Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-[5-11C]-glutamine
- Development stage
- Phase 1
- Lead developer
- Vanderbilt Center for Molecular Probes
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
L-[5-11C]-glutamine is a radiolabeled amino acid positron emission tomography (PET) tracer designed to study glutamine uptake and metabolism in vivo. It is used primarily for imaging tumors that exhibit increased glutaminolysis—a metabolic hallmark of many cancers, including colorectal cancer and gliomas. The tracer enables noninvasive visualization of tumor lesions by exploiting the elevated demand for glutamine in rapidly proliferating cancer cells. Mechanistically, it acts as a substrate analog for cellular glutamine transporters and metabolic pathways involved in protein synthesis and energy production via the tricarboxylic acid (TCA) cycle. In clinical studies, L-[5-11C]-glutamine PET has demonstrated safety and utility for detecting metastatic lesions in multiple organs, with potential applications in patient selection and monitoring response to therapy[1][2].
- Other names
- L-[5-^11C]-glutamine[^11C]Gln
02
Targets
OATP (Organic anion transporting polypeptides)Neuraminidase
Beyond the preview
Go deeper on L-[5-11C]-glutamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-[5-11C]-glutamine.